Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Celebrates Major Features Across Several Marquee Brazilian Press Outlets
Retrieved on:
Tuesday, November 1, 2022
Terra, Hype (marketing), CNBC, Criticism of the Food and Drug Administration, Epilepsy, Autism, Securities Exchange Act of 1934, Nature, Medical cannabis, The O.C., GLOBE, SBT, Securities Act of 1933, Degenerative disease, Disease, Chronic traumatic encephalopathy, Interview, Pan-American, Safe harbor, Safety, Chronic pain, Medical Marijuana, Inc., Folha de S.Paulo, Cannabis, Television, Parkinson's disease, RedeTV!, Veja, Food, Multiple sclerosis, Drug Quality and Security Act, SAN, OTC, CA, Coffee, Drug, Brazilian Health Regulatory Agency, CBD, Cannabidiol
The story was also picked up via syndication by additional large outlets in Brazil including Boa Forma, Terra, O Tempo, and Hypeness, among others.
Key Points:
- The story was also picked up via syndication by additional large outlets in Brazil including Boa Forma, Terra, O Tempo, and Hypeness, among others.
- We are thrilled that our products are enhancing lives and making a significant difference in the world, said HempMeds Brasil Executive Director Matheus Patelli.
- Awaiting publication are two recent feature interviews with HempMeds Brasil for Bloomberg Brazil and Veja, one of Brazils biggest magazines.
- Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.